ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,618.38
0.74%
US Tech 100
20,093.20
0.92%
Dow Jones
39,549.98
0.66%
Brent Oil
84.965
0.32%
Bitcoin
57,492.60
-0.91%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. GSK plc (GSK)

  7. GSK plc (GSK) News

GSK

GSK (GSK)

GSK plc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:GSK
DateTimeSourceHeadlineSymbolCompany
01/09/20245:52AMBusiness WireGSK Enters Agreement to Acquire Aiolos BioNYSE:GSKGSK plc
01/09/20243:35AMDow Jones NewsGSK Expands Respiratory Pipeline With Aiolos Bio Buy -- 2nd UpdateNYSE:GSKGSK plc
01/09/20243:04AMDow Jones NewsGSK Buys Aiolos Bio for Up to $1.4 Billion -- UpdateNYSE:GSKGSK plc
01/09/20242:39AMDow Jones NewsGSK Buys Aiolos Bio for Up to $1.4 BillionNYSE:GSKGSK plc
01/02/202410:35AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
12/21/202310:39AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
12/20/20238:27AMDow Jones NewsGSK Enters Exclusive License Agreement With Hansoh for HS-20093 Cancer AntibodyNYSE:GSKGSK plc
12/13/202311:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
12/12/20238:00AMBusiness WireGSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health EquityNYSE:GSKGSK plc
12/12/20236:06AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
12/11/20236:20AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
11/21/202311:09AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
11/15/202311:53AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
11/13/20238:00AMBusiness WireGSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness InitiativeNYSE:GSKGSK plc
11/13/20232:49AMDow Jones NewsGSK Gets Positive Opinion for Blood Cancer Drug From EU RegulatorNYSE:GSKGSK plc
11/01/20231:01PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
11/01/202312:51PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
11/01/20238:18AMDow Jones NewsTrending: GSK's 3Q Profits Drive Full-Year Guidance Hike, Despite Missing Market ViewsNYSE:GSKGSK plc
11/01/20234:20AMDow Jones NewsGSK PLC Raises Guidance After RSV Vaccine Lifts Earnings -- UpdateNYSE:GSKGSK plc
11/01/20233:50AMDow Jones NewsGSK PLC Raises Guidance After Strong PerformanceNYSE:GSKGSK plc
10/31/20237:24AMIH Market NewsTuesday’s Wall Street Highlights: Pinterest, BP, Wolfspeed, Arista, Lattice, Pfizer and moreNYSE:GSKGSK plc
10/30/20238:00AMGlobeNewswire Inc.23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSKNYSE:GSKGSK plc
10/30/20237:10AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
10/27/20237:00AMGlobeNewswire Inc.Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)NYSE:GSKGSK plc
10/25/20237:00AMBusiness WireNew Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV DiseaseNYSE:GSKGSK plc
10/20/202310:54AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
10/18/202312:24PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
10/17/202312:06PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
10/16/20237:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
10/13/202311:23AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:GSKGSK plc
 Showing the most relevant articles for your search:NYSE:GSK

Your Recent History

USOTC
MONI
Moon Equity (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
CYDY
CytoDyn (QB)
USOTC
WDLF
Decentral Life (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
SFRX
Seafarer Exploration (PK)
NASDAQ
AMRN
Amarin
USOTC
CNNA
Cann American (CE)
USOTC
GDVM
Global Developments (PK)
USOTC
TPTW
TPT Global Tech (PK)
USOTC
RNVA
Rennova Health (PK)
USOTC
RDGL
Vivos (QB)
NASDAQ
MAXN
Maxeon Solar Technologies
USOTC
CLNV
Clean Vision (QB)
AMEX
SPY
SPDR S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved